Literature DB >> 18451173

Exuberated numbers of tumor-specific T cells result in tumor escape.

Ofir Goldberger1, Ilan Volovitz, Arthur Machlenkin, Ezra Vadai, Esther Tzehoval, Lea Eisenbach.   

Abstract

Cytotoxic T cells (CTL) play a major role in tumor rejection. Expansion of CTLs, either by immunization or adoptive transfer, is a prominent goal in current immunotherapy. The antigen-specific nature of these expansion processes inevitably initiates a clonotypic attack on the tumor. By injecting an Ovalbumin-expressing melanoma into OT-I mice, in which >90% of CTLs recognize an Ovalbumin peptide, we show that an increased number of tumor-specific CTLs causes emergence of escape variants. We show that these escape variants are a result of antigen silencing via a yet undetermined epigenetic mechanism, which occurs frequently and is spontaneously reversible. We further show that an increase in the time of tumor onset in OT-I compared with C57BL/6J is a result of immune selection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18451173     DOI: 10.1158/0008-5472.CAN-07-5006

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.

Authors:  Trudy Straetemans; Cor Berrevoets; Miriam Coccoris; Elike Treffers-Westerlaken; Rebecca Wijers; David K Cole; Valerie Dardalhon; Andrew K Sewell; Naomi Taylor; Jaap Verweij; Reno Debets
Journal:  Mol Ther       Date:  2014-11-03       Impact factor: 11.454

2.  Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants.

Authors:  Karen M Kaluza; Jill M Thompson; Timothy J Kottke; Heather C Flynn Gilmer; Darlene L Knutson; Richard G Vile
Journal:  Int J Cancer       Date:  2011-11-30       Impact factor: 7.396

3.  Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors.

Authors:  Diana L Thomas; Rosalinda Doty; Vesna Tosic; Jia Liu; David M Kranz; Grant McFadden; Amy L Macneill; Edward J Roy
Journal:  Cancer Immunol Immunother       Date:  2011-06-09       Impact factor: 6.968

4.  mRNA-transfected Dendritic Cells Expressing Polypeptides That Link MHC-I Presentation to Constitutive TLR4 Activation Confer Tumor Immunity.

Authors:  Gal Cafri; Adi Sharbi-Yunger; Esther Tzehoval; Zoya Alteber; Tamar Gross; Ezra Vadai; Alon Margalit; Gideon Gross; Lea Eisenbach
Journal:  Mol Ther       Date:  2015-05-22       Impact factor: 11.454

5.  CD8+ T-cell responses rapidly select for antigen-negative tumor cells in the prostate.

Authors:  S Peter Bak; Mike Stein Barnkob; K Dane Wittrup; Jianzhu Chen
Journal:  Cancer Immunol Res       Date:  2013-09-20       Impact factor: 11.151

Review 6.  Oncolytic myxoma virus: the path to clinic.

Authors:  Winnie M Chan; Masmudur M Rahman; Grant McFadden
Journal:  Vaccine       Date:  2013-05-29       Impact factor: 3.641

7.  In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines.

Authors:  Tristan T Beaudette; Eric M Bachelder; Joel A Cohen; Allie C Obermeyer; Kyle E Broaders; Jean M J Fréchet; Eun-Suk Kang; Ines Mende; William W Tseng; Matthew G Davidson; Edgar G Engleman
Journal:  Mol Pharm       Date:  2009 Jul-Aug       Impact factor: 4.939

8.  Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence.

Authors:  Tim Kottke; Laura Evgin; Kevin G Shim; Diana Rommelfanger; Nicolas Boisgerault; Shane Zaidi; Rosa Maria Diaz; Jill Thompson; Elizabeth Ilett; Matt Coffey; Peter Selby; Hardev Pandha; Kevin Harrington; Alan Melcher; Richard Vile
Journal:  Cancer Immunol Res       Date:  2017-10-15       Impact factor: 11.151

Review 9.  Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions.

Authors:  Kevin J Curran; Hollie J Pegram; Renier J Brentjens
Journal:  J Gene Med       Date:  2012-06       Impact factor: 4.152

10.  Baculovirus capsid display potentiates OVA cytotoxic and innate immune responses.

Authors:  Paula Molinari; María I Crespo; María J Gravisaco; Oscar Taboga; Gabriel Morón
Journal:  PLoS One       Date:  2011-08-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.